Stereotaxis Closes Robocath Acquisition to Expand Surgical Robotics Reach
Stereotaxis has finalized its purchase of Robocath, adding robotic cardiology and neurointervention technology to its minimally invasive surgical portfolio.
Stereotaxis (NYSE: STXS) announced Wednesday that it has completed its acquisition of Robocath, a France-based developer of robotic systems for interventional cardiology and neurointerventions, marking a significant expansion of the St. Louis company's global surgical robotics footprint.
The deal, which had been previously announced, brings together two players in the minimally invasive endovascular space. Stereotaxis has long positioned itself as a pioneer in robotic-assisted surgical navigation, while Robocath — headquartered in Rouen, France — has focused on applying robotic precision to some of medicine's most technically demanding catheter-based procedures.
Read more Marex Acquires Bright Point International to Grow Asia Reach →
The combination stands to broaden Stereotaxis's addressable market beyond its existing cardiovascular robotics business, folding in Robocath's neurointervention capabilities at a time when demand for automated, minimally invasive procedures continues to grow across interventional medicine. The strategic logic reflects a broader industry trend of consolidation among surgical robotics firms seeking to offer more comprehensive procedural platforms to hospital systems worldwide.
For investors and clinicians alike, the completed transaction signals that Stereotaxis is accelerating its ambitions in the competitive medical robotics sector, where scale, technology breadth, and international reach are increasingly decisive advantages. The close of the acquisition positions the combined company to pursue expanded clinical adoption across both cardiac and neurological intervention suites.
Continue reading at GlobalNewswire.
